Hengqu (hetrombopag) / Jiangsu Hengrui Pharma - LARVOL DELTA

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. (clinicaltrials.gov) - P3 | N=213 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Sep 2024 ➔ Sep 2025 | Trial primary completion date: Sep 2024 ➔ Mar 2025

Enrollment closed • Trial completion date • Trial primary completion date • Hematological Disorders • Solid Tumor • Thrombocytopenia

Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia (clinicaltrials.gov) - P3 | N=100 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: May 2023 ➔ May 2025 | Trial primary completion date: May 2023 ➔ Dec 2024

Enrollment closed • Trial completion date • Trial primary completion date • Hematological Disorders • Immune Thrombocytopenic Purpura • Pediatrics • Thrombocytopenia • Thrombocytopenic Purpura

Efficacy and safety and analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data. (PubMed, Front Med (Lausanne)) - "The results indicated that, in terms of efficacy, romiplostim [odds ratio (OR), 0.04; 95% confidence interval (CI), 0 to 0.68] was the most effective, followed by avatrombopag, hetrombopag, and eltrombopag. In the context of clinical second-line treatment, the selection of the most suitable TPO-RA should be guided by the specific circumstances of each patient. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/#recordDetails."

Journal • Real-world evidence • Retrospective data • Review • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia. (PubMed, Ann Hematol) - "Old individuals are at a high risk of developing aplastic anemia, and immunosuppressive therapy (IST) based on anti-human T-lymphocyte immunoglobulin (ATG) and cyclosporine (CsA) is recommended for treating severe aplastic anemia (SAA)...Eltrombopag was administered at a dose of 75-150 mg/day, and hetrombopag was administered orally at a dose of 15 mg/day...In conclusion, treatment with porcine ATG and CsA was safe and effective in elderly patients with SAA. An extremely low baseline neutrophil count indicated a high risk of early death."

Journal • Anemia • Aplastic Anemia • Complement-mediated Rare Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Oncology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Comparison of the efficacy and safety of Hetrombopag and other thrombopoietin receptor agonists in the treatment of primary Immune thrombocytopenia (ChiCTR) - P=N/A | N=800 | Not yet recruiting | Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University

New trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

A clinical study protocol of hetrombopag combined with immunosuppressants for the treatment of severe aplastic anemia in children (ChiCTR) - P=N/A | N=68 | Not yet recruiting | Sponsor: Wuhan Children's Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology; Wuhan Children's Hospital affiliated to

New trial • Anemia • Aplastic Anemia • Hematological Disorders • IL4

SAFETY AND EFFICACY OF ROMIPLOSTIM FOR THE TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2025) - "Six patients had received oral small molecule TPO-R prior to romiplostim (avatrombopag=3, herombopag=2, eltrombopag=1), which was ineffective in all six cases. Our study shows that romiplostim alone or in combination with small molecule TPO-R agonists is effective and safe in the treatment of thrombocytopenia after allo-HSCT."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Transplantation

Comparison of Hetrombopag and Eltrombopag Added to First-Line Immunosuppressive Therapy in Severe Aplastic Anemia. (PubMed, Eur J Haematol) - " The addition of HPAG to standard IST in SAA patients showed similar response rates and response quality to that of EPAG. HPAG could be an alternative to EPAG for the first-line treatment of SAA patients."

Journal • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology

SAFETY AND EFFICACY OF ROMIPLOSTIM FOR THE TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2025) - "Six patients had received oral small molecule TPO-R prior to romiplostim (avatrombopag=3, herombopag=2, eltrombopag=1), which was ineffective in all six cases. Our study shows that romiplostim alone or in combination with small molecule TPO-R agonists is effective and safe in the treatment of thrombocytopenia after allo-HSCT."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Transplantation

Successful treatment of refractory systemic lupus erythematosus-associated immune thrombocytopenia with drug-induced liver injury with telitacicept: a case report and review. (PubMed, Front Immunol) - "The use of dexamethasone(DEX), cyclosporine A(CsA), and hetrombopag resulted in drug-induced liver injury. Subsequently, telitacicept was chosen and successfully controlled the patient's condition. It suggests that telitacicept may be a new treatment option for refractory SLE-ITP."

Journal • Hematological Disorders • Hepatology • Immune Thrombocytopenic Purpura • Immunology • Inflammatory Arthritis • Liver Failure • Lupus • Systemic Lupus Erythematosus • Thrombocytopenia • Thrombocytopenic Purpura

A Single-center, Exploratory Clinical Study of the Efficacy and Safety of Hyaltopa Ethanolamine Tablets in the Treatment of Thrombocytopenia Caused by Concurrent/Sequential Chemoradiotherapy (ChiCTR) - P=N/A | N=30 | Completed | Sponsor: Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University

New trial • Hematological Disorders • Oncology • Thrombocytopenia

Efficacy and Safety of Hetrombopag Plus rhIL-11 for Chemotherapy-Induced Thrombocytopenia in Cancer Patients (ChiCTR) - P=N/A | N=300 | Not yet recruiting | Sponsor: Affiliated Qingyuan Hospital, Guangzhou Medical University,Qingyuan People's Hospital;; Affiliated Qingyuan Hospital, Guangzhou Medical University,Qin

New trial • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia

Study on the effectiveness and safety of Hetrombopag in promoting platelet reconstruction after umbilical cord blood transplantation in children or adolescents (ChiCTR) - P=N/A | N=60 | Not yet recruiting | Sponsor: Children's Hospital of Soochow University; Children's Hospital of Soochow University

New trial • Bone Marrow Transplantation • Hematological Disorders • Thrombocytopenia • Transplantation

Hetrombopag treatment for immune thrombocytopenia in pregnancy refractory to corticosteroids and intravenous immunoglobulin: a case report. (PubMed, Front Med (Lausanne)) - "Herein, we report a case of a 31-year-old pregnant woman with recurrent and refractory ITP who was safely and effectively treated with hetrombopag, with no influence on the infant's platelet count. This case explores a new treatment option for the management of recurrent and refractory ITP in pregnancy."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies (clinicaltrials.gov) - P2 | N=52 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Trial completion date: Sep 2024 ➔ Sep 2025

Trial completion date • Hematological Disorders • Immune Thrombocytopenic Purpura • Rheumatology • Thrombocytopenia • Thrombocytopenic Purpura

Herombopag for Chemotherapy-induced Thrombocytopenia (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Mar 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia

A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P2 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia (clinicaltrials.gov) - P2 | N=54 | Completed | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Active, not recruiting ➔ Completed | Trial completion date: May 2025 ➔ Jan 2025

Trial completion • Trial completion date • Anemia • Aplastic Anemia • Hematological Disorders

A Prospective, Single-arm, Multicenter Clinical Study of the Efficacy and Safety of Hetrombopag in the Treatment of Adults with Low-Risk Myelodysplastic Syndrome and Thrombocytopenia (ChiCTR) - P=N/A | N=43 | Recruiting | Sponsor: The First Affiliated Hospital of Zhejiang University Medical College; The First Affiliated Hospital of Zhejiang University Medical College | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • Thrombocytopenia

A clinical trial of hetrombopag in the treatment of delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation (ChiCTR) - P4 | N=48 | Recruiting | Sponsor: The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of Universi | Not yet recruiting ➔ Recruiting | N=84 ➔ 48

Enrollment change • Enrollment open • Bone Marrow Transplantation • Transplantation

A prospective, multicenter, randomized, controlled clinical trial of Herombopag Olamine Tablets in the prevention of thrombocytopenia in children with acute lymphoblastic leukemia during myelosuppression (ChiCTR) - P4 | N=252 | Recruiting | Sponsor: Affiliated Hospital of Guizhou Medical University; Affiliated Hospital of Guizhou Medical University

New P4 trial • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Thrombocytopenia

A multicenter clinical and translational study of three types of thrombopoietin receptor agonists in the treatment of childhood immune thrombocytopenia (ChiCTR) - P4 | N=90 | Recruiting | Sponsor: Fuyang People's hospital; Fuyang People's hospital

New P4 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

A ClinicaI Investigation on the Safety and Effectiveness of Hetrombopag for the Secondary Prevention of Thrombocytopenia Associated with the Treatment of Lymphoma (ChiCTR) - P1/2 | N=30 | Sponsor: The Affiliated Cancer Hospital of Shandong First Medical University; The Affiliated Cancer Hospital of Shandong First Medical University

New P1/2 trial • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Thrombocytopenia

A prospective, single arm, multicenter clinical study on the efficacy and safety of Hetrombopag Olamine Tablets combined with cyclosporine in the treatment of low-risk adult patients with myelodysplastic syndrome and thrombocytopenia (ChiCTR) - P=N/A | N=24 | Sponsor: The First People's Hospital of Zhenjiang City; The First People's Hospital of Zhenjiang City

New trial • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • Thrombocytopenia

Efficacy and safety of hetrombopag plus high-dose dexamethasone in newly diagnosed primary immune thrombocytopenia (ChiCTR) - P=N/A | N=46 | Recruiting | Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University

New trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura